The new Congress should promote patient centered care, increase accessibility, affordability, and transparency.

Expanding benefits for medicare will hasten the program’s impending depletion. 

Like many other well-intended programs 340B has ended up both wasting money and failing to provide benefits for patients.

Prices controls have always disrupted the marketplace and created shortages or excesses.

At a Capitol Hill briefing on the urgent need for reforms to the 340B Drug Pricing Program, the case was made for prompt action to fix the program.  The event took place at the Senate Visitors Center on September 23, 2024, and was hosted by the Council for Citizens Against Government Waste (CCAGW).

The panel was moderated by Monica Popp, founding partner of Marshall and Popp, and the speakers were CCAGW President Tom Schatz; Pioneer Institute Senior Fellow & Director of Pioneer Life Sciences Initiative Dr. William Smith; and Patients Rising Chief Mission Officer Terry Wilcox.

USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.

The Inflation Reduction Act creates instability in the Medicare Part D Program.

The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.